Background: Staphylococcus and Aeromonas bacteria are pathogens in humans and animals. The therapy disrupts the virulence structure of the bacteria, resulting in bacterial death. Currently, chemical drugs have resulted in many resistant bacteria, so it is necessary to find alternative natural materials that are not toxic and do not quickly induce resistance.
Aims: This study aimed to analyze the potential of methanol extract from BSF prepupa as an antibacterial agent against S. aureus and Aeromonas through in silico and in vitro tests.
Methods: The BSF prepupae methanol extract was then analyzed for protein and fatty acid contents. Molecular docking of the active ingredients (defensin, chitin, and chitosan as well as fatty acids) in BSF was downloaded from the NCBI database and docked with the Hex Cuda 8.0 program, Correlation type parameters Shape + Electro and Grid Dimension 0.6. Docking results were analyzed using the Discovery Studio program version 21.1.1.
Results: The highest fatty acid contents in the extract were palmitic acid and myristic acid. Methanol extract from BSF prepupae acted as a bactericidal agent against S. aureus at a concentration of 320 mg/ml, in contrast to Aeromonas, which still showed bacterial growth. The results of the in silico test showed that defensin–aerolysin and defensin–hemolysin were bound to the same active site area. However, the amount of binding energy produced by 69-Defensin-83-aerolysin was higher than all defensin types in BSF against Aeromonas. Chitin and chitosan showed a bond on the active site of aerolysin and hemolysin, but chitosan had a stronger bond than chitin. In silico study also showed the strongest binding affinity of BSF fatty acids to isoleucyl-tRNA synthetase of S. aureus.
Conclusion: The study showed that methanol extract from BSF prepupae had more potential as an antibacterial agent against S. aureus than Aeromonas in vitro and in silico.
Results: Overall survival (OS) and disease-free survival (DFS) of patients with sMPMTs was 77% and 70% at 2 years, which were not statistically different with those without sMPMTs (P ¼.17 and P ¼.64). The cumulative incidence of relapse was 24% at 2 years, and there was statistically no significant difference between patients with and without sMPMTs (P ¼.84). Results of multivariate analysis showed that presence of sMPMTs was not a significant prognostic factor for OS, DFS, and relapse [Hazard ratio (HR) 1.48 95%CI (0.65-3.38), P¼.35; HR 0.97 95%CI (0.46-2.10), P¼.97; HR 0.79 95%CI (0.29-2.14), P¼.65]. In patients with sMPMTs, the order of treatment was not a significant prognostic factor. On the other hand, discontinuation of treatment was a marginal favorable factor, which might reflect a selection bias. Conclusions: Existence of sMPMTs was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment for both hematological malignancy and solid tumor at physician's discretion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.